Valo will use its trove of patient records and biobank samples to pinpoint potential targets for Merck’s pipeline expansion.

Innovative linkers, connecting antibodies to payloads, are fine-tuning ADC selectivity while broadening their therapeutic scope.

Moderna has announced the expansion of its US manufacturing capabilities with the onshoring of drug product manufacture to Massachusetts.

Novartis' two new sites in North Carolina fall under the Swiss pharma’s $23bn US manufacturing onshoring ploy.

Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication to its label and offering a more convenient dosing option, as the drugmaker ...

Mesenchymal stem cells have been explored across a wide range of diseases due to their potential to reduce inflammation and promote tissue repair and regeneration.

Pfizer and Tris Pharma have agreed to pay $41.5m to settle allegations by the Texas Attorney General Ken Paxton ...

Roche has conditional marketing authorisation from the EC for Lunsumio SC for adults with R/R FL after at least two systemic therapies.

Alkermes will likely proceed with its planned acquisition of Avadel, which experienced an unexpected hitch following Lundbeck’s counteroffer.

The US FDA has granted approval for AbbVie’s Epkinly to treat adult patients with relapsed or refractory (R/R) follicular lymphoma (FL).

CSL said the investment reflects the growing need for immunoglobulin, though it did not reveal detailed manufacturing plans.

Redemplo’s approval in familial chylomicronemia syndrome places the drug in competition with Ionis’ Tryngolza.